Shownotes
"Time is tissue." That’s what one biotech exec told me after losing a clinical trial participant due to regulatory delays.
In a landmark 2025 announcement, HHS Secretary Robert F. Kennedy Jr. unveiled a sweeping plan to streamline the FDA approval process for rare disease treatments—a move biotech insiders are calling "a long-overdue revolution."
With over 30 million Americans living with rare diseases, most of whom lack FDA-approved treatments, this shift could redefine not only how quickly patients get help—but also where the next wave of biotech innovation happens. In an age when gene and…
Website: podcasters.spotify.com

